Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 1
1990 7
1992 2
1993 2
1994 3
1995 6
1996 3
1997 6
1998 4
1999 8
2000 5
2001 6
2002 7
2003 8
2004 4
2005 9
2006 2
2007 3
2008 6
2009 3
2010 6
2011 1
2012 1
2013 3
2014 4
2015 2
2016 6
2017 7
2018 11
2019 11
2020 10
2021 14
2022 13
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Results by year

Filters applied: . Clear all
Page 1
Consensus on diagnosis and management of Cushing's disease: a guideline update.
Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK. Fleseriu M, et al. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. Lancet Diabetes Endocrinol. 2021. PMID: 34687601 Free PMC article. Review.
Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management to optimise patient outcomes. The Pituitary Society convened a consensus workshop comprising more than 50 academic researchers and clinical experts to discuss the applicati …
Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management to optimise patient outcomes. The Pi
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S. Petersenn S, et al. Nat Rev Endocrinol. 2023 Dec;19(12):722-740. doi: 10.1038/s41574-023-00886-5. Epub 2023 Sep 5. Nat Rev Endocrinol. 2023. PMID: 37670148 Review.
This Consensus Statement from an international, multidisciplinary workshop sponsored by the Pituitary Society offers evidence-based graded consensus recommendations and key summary points for clinical practice on the diagnosis and management of prolactinomas. Epidemiology …
This Consensus Statement from an international, multidisciplinary workshop sponsored by the Pituitary Society offers evidence-based g …
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A; Endocrine Society. Nieman LK, et al. J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29. J Clin Endocrinol Metab. 2015. PMID: 26222757 Free PMC article.
The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient....
The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), …
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. Brastianos PK, et al. N Engl J Med. 2023 Jul 13;389(2):118-126. doi: 10.1056/NEJMoa2213329. N Engl J Med. 2023. PMID: 37437144 Free PMC article. Clinical Trial.
BACKGROUND: Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. ...
BACKGROUND: Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequ …
ICAR: endoscopic skull-base surgery.
Wang EW, Zanation AM, Gardner PA, Schwartz TH, Eloy JA, Adappa ND, Bettag M, Bleier BS, Cappabianca P, Carrau RL, Casiano RR, Cavallo LM, Ebert CS Jr, El-Sayed IH, Evans JJ, Fernandez-Miranda JC, Folbe AJ, Froelich S, Gentili F, Harvey RJ, Hwang PH, Jane JA Jr, Kelly DF, Kennedy D, Knosp E, Lal D, Lee JYK, Liu JK, Lund VJ, Palmer JN, Prevedello DM, Schlosser RJ, Sindwani R, Solares CA, Tabaee A, Teo C, Thirumala PD, Thorp BD, de Arnaldo Silva Vellutini E, Witterick I, Woodworth BA, Wormald PJ, Snyderman CH. Wang EW, et al. Int Forum Allergy Rhinol. 2019 Jul;9(S3):S145-S365. doi: 10.1002/alr.22326. Int Forum Allergy Rhinol. 2019. PMID: 31329374
RESULTS: The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign skull-base and orbital pathology, sinonasal malignancies, and clival lesions. ...CONCLUSION: A critical review of the literature in ESBS de …
RESULTS: The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign …
Fluorescence guided surgery for pituitary adenomas.
Lakomkin N, Van Gompel JJ, Post KD, Cho SS, Lee JYK, Hadjipanayis CG. Lakomkin N, et al. J Neurooncol. 2021 Feb;151(3):403-413. doi: 10.1007/s11060-020-03420-z. Epub 2021 Feb 21. J Neurooncol. 2021. PMID: 33611707 Review.
PURPOSE: Resection of pituitary adenomas presents a number of unique challenges in neuro-oncology. ...Both in vitro and in vivo studies were assessed. The application of these agents to pituitary tumors, their advantages and limitations, as well as future dir …
PURPOSE: Resection of pituitary adenomas presents a number of unique challenges in neuro-oncology. ...Both in vitro and in vivo studi …
Genetic and epigenetic characterization of posterior pituitary tumors.
Schmid S, Solomon DA, Perez E, Thieme A, Kleinschmidt-DeMasters BK, Giannini C, Reinhardt A, Asa SL, Mete O, Stichel D, Siewert C, Dittmayer C, Hasselblatt M, Paulus W, Nagel C, Harter PN, Schittenhelm J, Honegger J, Rushing E, Coras R, Pfister SM, Buslei R, Koch A, Perry A, Jones DTW, von Deimling A, Capper D, Lopes MB. Schmid S, et al. Acta Neuropathol. 2021 Dec;142(6):1025-1043. doi: 10.1007/s00401-021-02377-1. Epub 2021 Oct 18. Acta Neuropathol. 2021. PMID: 34661724 Free PMC article.
Pituicytoma (PITUI), granular cell tumor (GCT), and spindle cell oncocytoma (SCO) are rare tumors of the posterior pituitary. Histologically, they may be challenging to distinguish and have been proposed to represent a histological spectrum of a single entity. ...In …
Pituicytoma (PITUI), granular cell tumor (GCT), and spindle cell oncocytoma (SCO) are rare tumors of the posterior pituitary. …
The molecular pathogenesis of craniopharyngiomas.
Campanini ML, Almeida JP, Martins CS, de Castro M. Campanini ML, et al. Arch Endocrinol Metab. 2023 Mar 10;67(2):266-275. doi: 10.20945/2359-3997000000600. Epub 2023 Feb 7. Arch Endocrinol Metab. 2023. PMID: 36748936 Free PMC article. Review.
Besides the well-known clinical and histological differences between the subtypes of CPs, adamantinomatous (ACP) and papillary (PCP) craniopharyngiomas, other molecular differences have been identified, further elucidating pathways related to the origin and development of such …
Besides the well-known clinical and histological differences between the subtypes of CPs, adamantinomatous (ACP) and papillary (PCP) craniop …
Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients.
Guaraldi F, Morandi L, Zoli M, Mazzatenta D, Righi A, Evangelisti S, Ambrosi F, Tonon C, Giannini C, Lloyd RV, Asioli S. Guaraldi F, et al. Clin Endocrinol (Oxf). 2022 Dec;97(6):763-772. doi: 10.1111/cen.14827. Epub 2022 Oct 7. Clin Endocrinol (Oxf). 2022. PMID: 36161330 Free PMC article.
OBJECTIVE: To profile clinically non-aggressive and aggressive pituitary adenomas (PAs)/pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas for somatic mutations and epigenetic alterations of genes involved in cell proliferation/differentiatio …
OBJECTIVE: To profile clinically non-aggressive and aggressive pituitary adenomas (PAs)/pituitary neuroendocrine tumours (PitN …
Identification and consequences of galectin-3 expression in pituitary tumors.
Righi A, Jin L, Zhang S, Stilling G, Scheithauer BW, Kovacs K, Lloyd RV. Righi A, et al. Mol Cell Endocrinol. 2010 Sep 15;326(1-2):8-14. doi: 10.1016/j.mce.2010.04.026. Epub 2010 May 6. Mol Cell Endocrinol. 2010. PMID: 20451577 Review.
Although the mechanisms regulating pituitary tumor development and progression are still unclear, new information on the molecular mechanisms involved in the pathogenesis of human pituitary tumors have accumulated. ...This review summarizes existing informati …
Although the mechanisms regulating pituitary tumor development and progression are still unclear, new information on the molecular me …
193 results